Postoperative Analgesia after Breast Reduction Surgery Comparing Liposomal Bupivacaine versus 0.25% Bupivacaine Hydrochloride

Overview

About this study

The purpose of this study is to compare liposomal bupivacaine and 0.25% Bupivacaine Hydrochloride as local infiltration.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult female patients (18-70 years old) with symptomatic macromastia scheduled for breast reduction using a Wise pattern incision design.

Exclusion Criteria:

  • Exclusion criteria include inability to provide informed consent, medical or surgical history precluding breast reduction, history of significant chronic pain requiring daily use of opioid or nonopioid analgesics, pregnancy, concomitant non-breast surgical procedure, previous chest wall irradiation, previous breast implant, breast reduction or breast lift surgery, known allergy to bupivacaine or liposomal bupivacaine, liver or kidney dysfunction, use of antiplatelet or anticoagulation therapy.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/11/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Basel Sharaf, M.D., D.D.S.

Open for enrollment

Contact information:

Jennifer Krogman

(507) 538-3320

Krogman.Jennifer@mayo.edu

More information

Publications

Publications are currently not available